- Poster presentation
- Open Access
T1 mapping: useful for treatment monitoring in patients with senile systemic amyloidosis?
© dem Siepen et al.; licensee BioMed Central Ltd. 2014
- Published: 16 January 2014
- Left Ventricular Volume
- Daily Consumption
- Short Axis Slice
- EGCG Treatment
- Amyloid Load
Recent reports indicate that epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea, is potent to inhibit fibril formation of several amyloidogenic proteins in vitro. In vivo studies revealed reduction of left ventricular myocardial mass (LVM) after 12 months of daily consumption of 450 mg EGCG. However, the underlying process of LVM reduction, either due to reduction of amyloid or due to atrophy of cardiomyocytes, remained unknown. T1-mapping has the potential to monitor the extent of the extracellular volume (ECV). We sought to investigate the use of T1 mapping for monitoring of treatment effects in a cohort of patients with senile systemic amyloidosis (SSA) treated with EGCG for 12 months.
This is a preliminary study to evaluate T1-mapping for the monitoring of treatment effects in patients with SSA. The decrease of T1 relaxation time after 12 months of EGCG treatment might possibly indicate a reduction of amyloid load. Thus, T1-mapping might be a potential tool for monitoring further experimental therapies. However, the considerable gap between native T1 and ECV measurements remain unexplained and needs to be investigated in a future study.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.